The histone demethylase inhibitor GSK-J4 limits inflammation through the induction of a tolerogenic phenotype on DCs
Cargando...
Fecha
2016-12
Autores
Doñas, Cristian
Carrasco, Macarena
Fritz, Macarena
Prado, Carolina
Tejón, Gabriela
Osorio-Barrios, Francisco
Manríquez, Valeria
Reyes, Paz
Pacheco, Rodrigo
Bono, María Rosa
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
Academic Press
Nombre de Curso
Licencia CC
Atribution 4.0 International (CC BY 4.0)
Licencia CC
https://creativecommons.org/licenses/by/4.0/deed.es
Resumen
As it has been established that demethylation of lysine 27 of histone H3 by the lysine-specific deme thylase JMJD3 increases immune responses and thus elicits inflammation, we hypothesize that inhibition
of JMJD3 may attenuate autoimmune disorders.
We found that in vivo administration of GSK-J4, a selective inhibitor of JMJD3 and UTX, ameliorates the
severity of experimental autoimmune encephalomyelitis (EAE). In vitro experiments revealed that the
anti-inflammatory effect of GSK-J4 was exerted through an effect on dendritic cells (DCs), promoting a
tolerogenic profile characterized by reduced expression of costimulatory molecules CD80/CD86, an
increased expression of tolerogenic molecules CD103 and TGF-b1, and reduced secretion of proin flammatory cytokines IL-6, IFN-g, and TNF. Adoptive transfer of GSK-J4-treated DCs into EAE mice
reduced the clinical manifestation of the disease and decreased the extent of inflammatory CD4þ T cells
infiltrating the central nervous system. Notably, Treg generation, stability, and suppressive activity were
all exacerbated by GSK-J4-treated DCs without affecting Th1 and Th17 cell production. Our data show
that GSK-J4-mediated modulation of inflammation is achieved by a direct effect on DCs and that systemic
treatment with GSK-J4 or adoptive transfer of GSK-J4-treated DCs ex vivo may be promising approaches
for the treatment of inflammatory and autoimmune disorders.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Notas
Indexación: Scopus.
Palabras clave
GSK-J4, Autoimmunity, DCs, Treg, JMJD3, H3K27me3
Citación
Journal of Autoimmunity. Volume 75, Pages 105 - 117. 1 December 2016
DOI
10.1016/j.jaut.2016.07.011